Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of “Moderate Buy” by Brokerages

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $13.57.

Several research firms have weighed in on IRWD. Leerink Partners assumed coverage on Ironwood Pharmaceuticals in a research report on Monday, September 9th. They set a “market perform” rating and a $5.00 price target on the stock. Craig Hallum reduced their target price on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 16th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Finally, Wells Fargo & Company reduced their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, August 9th.

Ironwood Pharmaceuticals Stock Down 4.7 %

NASDAQ:IRWD opened at $4.30 on Monday. The firm has a market capitalization of $673.07 million, a price-to-earnings ratio of -0.63 and a beta of 0.49. Ironwood Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $15.70. The stock’s 50 day moving average price is $5.34 and its two-hundred day moving average price is $6.60.

Insider Activity at Ironwood Pharmaceuticals

In related news, insider Minardo John sold 9,910 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $4.27, for a total value of $42,315.70. Following the completion of the sale, the insider now directly owns 284,661 shares in the company, valued at approximately $1,215,502.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC acquired a new position in Ironwood Pharmaceuticals in the 2nd quarter valued at $313,000. Algert Global LLC acquired a new position in Ironwood Pharmaceuticals in the 2nd quarter valued at $93,000. Dark Forest Capital Management LP raised its holdings in Ironwood Pharmaceuticals by 16.5% in the 2nd quarter. Dark Forest Capital Management LP now owns 60,386 shares of the biotechnology company’s stock valued at $394,000 after acquiring an additional 8,557 shares in the last quarter. AQR Capital Management LLC raised its holdings in Ironwood Pharmaceuticals by 45.7% in the 2nd quarter. AQR Capital Management LLC now owns 684,578 shares of the biotechnology company’s stock valued at $4,463,000 after acquiring an additional 214,836 shares in the last quarter. Finally, Armistice Capital LLC raised its holdings in Ironwood Pharmaceuticals by 44.4% in the 2nd quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock valued at $50,856,000 after acquiring an additional 2,400,000 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.